Skip to main content

BC Cancer – Vancouver



If you are interested in more information about a particular trial, please talk with your treating physician first, and they may contact this centre for further information if necessary.

Tumour group / siteTrial titleDate opened
BREAST


CARA Pilot STUDY:  A Novel Breast Positioning Device to Reduce Toxicity in Radiotherapy for Breast Cancer
BCCA CODE: CARA
Sept 2018

Prospective Outcomes and Support Initiative: Breast Skin Pilot (B-SkiP)
BCCA CODE: POSI B-SkiP
Aug 2018

A phase IIIb, single-arm, open-label multicentre study of olaparib monotherapy in the treatment of HER2-ve metastatic breast cancer patients with germline BRCA1/2 mutations
BCCA CODE: BRTLUCY
18 May 2018

A Randomized Phase III Double Blinded Placebo Controlled Trial Of Aspirin As Adjuvant Therapy For HER2 Negative Breast Cancer: The ABC Trial
BCCA CODE: BRMAC21 
9 May 2018

A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE III STUDY OF IPATASERTIB IN COMBINATION WITH PACLITAXEL AS A TREATMENT FOR PATIENTS WITH PIK3CA/AKT1/PTEN-ALTERED, LOCALLY ADVANCED OR METASTATIC, TRIPLE-NEGATIVE BREAST CANCER OR HORMONE RECEPTOR–POSITIVE, HER2-NEGATIVE BREAST CANCER
BCCA CODE: BRTIPATUNI
01 May 2018

A phase II, multicenter, open-label, two-cohort, non-comparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, horone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after CDK 4/6 inhibitor treatment
BCCA CODE: BRTBYLIEVE
March 2018

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
BCCA CODE: BRMA37
September 2017

A study evaluating the pregnancy outcomes and safety of interupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy (positive)
BCCA CODE: BRMAC18

July 2017

Treatment of Canadian Postmenopausal Women with ER+ Advanced Breast Cancer in the Real-World Setting with Hormone Therapy
BCCA CODE: BRTYCA09

November 2016

A randomised, double-blind, parallel group, placebo-controlled multi-centre phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy
BCCA CODE: BRMA36
February 2016
CENTRAL NERVOUS
SYSTEM (CNS)

GASTROINTESTINAL (GI)

An open-label, multi-center, Phase 1b study to investigate the safety and tolerability of SLC-0111 (WBI-5111)1 in combination with gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma subjects positive for Carbonic Anhydrase IX

BCCA CODE: GITSLCGEM

10 Jan 2019

Neoadjuvant chemotherapy, Excision and Observation for early rectal cancer (CCTG)
BCCA CODE: GICO28
21 Jun 2018

A PHASE III, RANDOMISED, INTERNATIONAL TRIAL COMPARING mFOLFIRINOX TRIPLET CHEMOTHERAPY TO mFOLFOX FOR HIGH RISK STAGE III COLON CANCER IN ADJUVANT SETTING (IROCAS STUDY)
BCCA CODE: GICO27
April 2018

COMPHREHENSIVE GENOMIC PROFILING OF COLORECTAL CANCER PATIENTS WITH ISOLATED LIVER METASTASES TO UNDERSTAND RESPONSE & RESISTANCE TO CANCER THERPAY 
BCCA CODE: GICOMPARIS
April 2018

Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma subtypes by comprehensive Genomic Analysis
BCCA CODE: GITPANGEN
February 2017

A randomized multicenter double blind phase III study of nivolumab or placebo in subjects with resected lower esophageal or gastroesophageal junction cancer
BCCA CODE: GIT209577

September 2016

 
A phase lll study of the impact of a physical activity program on disease-free survival in patients with high risk stage ll or stage lll colon cancer: a randomized controlled trial (challenge)
BCCA CODE: GICO21
July 2009

GENITOURINARY (GU) - BLADDER

A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer
BCCA CODE: GUTNILE

5 Feb 2019

A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations
BCCA CODE: GUTTHOR
4 Jan 2019

An Open-label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)        
BCCA CODE: GUTEV301
13 Dec 2018

A phase III, open-label, multicenter, randomized study of atezolizumab (anti-PD-L1 antibody) versus observation as adjuvant therapy in patients with PD-L1-selected, high risk muscle-invasive bladder cancer after cystectomy
BCCA CODE: GUT29636
March 2016
GENITOURINARY (GU) - Kidney

A Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse

BCCA CODE: GUT914


22 Aug 2018


A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma (CLEAR)
BCCA CODE: GUTCLEAR
5 Jul 2018
A multi-center, open label, randomized phase II study of AGS-16C3F vs axitinib in metastatic renal cell carcinoma
BCCA CODE: GUT16C3F
April 2016
GENITOURINARY (GU) - TestisSurgery in Early Metastatic Seminoma (SEMS): Phase II Trial of Retroperitoneal Lymph Node Dissection as First-Line Treatment for Testicular Seminoma with Isolated Retroperitoneal Disease (1-3cm)
BCCA CODE: GUSEMS
11 Sep 2018
GENITOURINARY

(GU) - Prostate

VISION: AN INTERNATIONAL, PROSPECTIVE, OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF 177LU-PSMA-617 IN THE TREATMENT OF PATIENTS WITH PROGRESSIVE PSMA-POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) 
BCCA CODE: GUTVISION

17 Jan 2019


A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer 
BCCA CODE: GUTQUEST

30 Oct 2018

A Phase II Study of Palbociclib, a CDK4/6 Inhibitor, In Patients With Metastatic Castration-Resistant Prostate 
BCCA CODE: GUIND223
22 Aug 2018

Prostate Cancer Biomarker Enrichment and Treatment Selection (PC-BETS) Study
BCCA CODE: GUIND234
22 Aug 2018

A Multicentre Cohort Study of Patients with Advanced Prostate Cancer in Canada
BCCA CODE: GURC
3 Jul 2018

An International Registry for Men with Advanced Prostate Cancer
BCCA CODE: IRONMAN
April 2018

A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
BCCA CODE: GUTCR2001
December 2017

A Safety and Pharmacokinetics Study of Niraparib plus Androgen Receptor-Targeted Therapy (Apalutamide or Abiraterone Acetate plus Prednisone) in Men with Metastatic Castration-Resistant Prostate Cancer

BCCA CODE: GUTBEDIVER

June 2017

A phase II study of durvalumab (MEDI4736) with or without tremelimumab in patients with castration resistant prostate cancer
BCCA CODE: GUIND232
January 2017

A phase I/II open-label study to assess the safety, pharmcokinetics, and anti-tumor activity of oral EPI-506 in patients with metastatic castration-resistant prostate cancer
BCCA CODE: GUTCS0001
(on HOLD as of January 9, 2015)
December 2015
GYNECOLOGY
An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810 Versus Therapy of Investigator’s Choice Chemotherapy in Recurrent or Metastatic Platinum-Refractory Cervical Carcinoma 
BCCA CODE: GOTEMPOWER
04 Oct 2018

Phase I (Safety Assessment) of Durvalumab (MEDI4736) with Focal Sensitizing Radiotherapy in Platinum Resistant Ovarian, Primary Peritoneal or Fallopian Tube Epithelial Carcinoma
BCCA CODE: GOTABSRT (re-opened 21Dec2018)
28 May 2018

A Retrospective/
Prospective Analysis of Characterization of the Long-Term Responders on Olaparib in Solid Tumours

BCCA CODE: 
GOTOZM061

August 2017

A phase 3 randomized, double-blind, placebo-controlled multicentre study of Niraparib maintenance treatment in patients with HRD-positive advanced ovarian cancer following response to front-line platinum-based chemotherapy
BCCA CODE: GOTPRIMA
February 2017
HEAD & NECK

LUNG
A PHASE II STUDY OF POZIOTINIB IN PATIENTS WITH NON-SMALL CELL LUNG CANCER, LOCALLY ADVANCED OR METASTATIC, WITH EGFR OR HER2 EXON20 INSERTION MUTATION
BCCA CODE: LUTPOZ202
4 Dec 2018


A Phase III, open-label, multicenter, randomized study to investigate the efficacy and safety of atezolizumab compared with chemotherapy in patients withtreatment-naïve advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) non-small cell lung cancer who are deemed unsuitable for platinum-containing therapy

BCCA CODE: LUT29872

December 2017


A phase III prospective double blind placebo controlled randomized study of adjuvant MEDI4736 in completely resected non-small cell lung cancer
BCCA CODE: LUBR31
July 2015
LYMPHOMA

A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB AND CHP (R-CHP) VERSUS RITUXIMAB AND CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA 
BCCA CODE: LYTPOLARIX

28 Feb 2019

A PHASE IB/II STUDY EVALUATING THE SAFETY, TOLERABILITY AND ANTI-TUMOR ACTIVITY OF POLATUZUMAB VEDOTIN (DCDS4501A) IN COMBINATION WITH RITUXIMAB (R) OR OBINUTUZUMAB (G) PLUS BENDAMUSTINE (B) IN RELAPSED OR REFRACTORY FOLLICULAR OR DIFFUSE LARGE B-CELL LYMPHOMA 
BCCA CODE: LYT29365 (re-opened with Arm H)
2 Jan 2019

BGB-A317-207 A Phase 2, Open-Label Study of BGB-A317 in Patients with Relapsed or Refractory Mature T- and NK-cell Neoplasms 
BCCA CODE:
LYTBGBA317
1 Nov 2018

A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients with CD30-Positive Peripheral T-cell Lymphoma 
BCCA CODE: LYTCHEPBV
10 Sep 2018

Phase 3 Study of Ibrutinib in Combination With Venetoclax in Subjects with Mantle Cell Lymphoma

Pharmacyclics PCYC-1143-CA

BCCA CODE: LYTPCYC (Part 2 opened 3Aug2018)

18 Jul2018

A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Relapsed or Refractory B-Cell Malignancies
BCCA CODE: LYT224022
24 May 2018

A Phase 3, Randomized, Double‑blind, Placebo‑controlled, Multicenter Study of BR alone Versus in Combination with Acalabrutinib (ACP‑196) in Subjects with Previously Untreated Mantle Cell Lymphoma. (ACE-LY-308 ECHO MCL study)

BCCA CODE: LYTACE308

26 Sep 2017

A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects with Relapsed or Refractory Hematologic malignancies
BCCA CODE: LYTTT1621

May 2017

An open-label, multicenter, phase I trial evaluating the safety and pharmacokinetics of escalating doses of BTCT4465A in patients with relapsed or refractory B-cell non-hodgkin's lymphoma and chronic lymphocytic leukemia (CLL)
BCCA CODE: LYT29781
February 2016

A phase I/II study to evaluate the safety and preliminary efficacy of nivolumab in combination with brentuximab vedotin in subjects with relapsed refractory non-hodgkin lymphomas with CD30 expression CheckMate 436: CHECKpoint pathway and nivolumab clinical trial evaluation
BCCA CODE: LYT209436
December 2015

A multi-staged randomized phase II study of novel combination therapy in the treatment of relapsed and refractory aggressive B-cell lymphoma
BCCA CODE: LYLY17
September
2015

A phase IB/II, open-label study evaluting the safety and pharmacokenetics of GDC-0199 (ABT-199) in combination with rituximab(R) or obinutuzumab(G) plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with B-cell non-hodgkin's lymphoma (NHL) and DLBCL
BCCA CODE: LYT27878
February 2015

PHASE 1

A PHASE II OPEN LABEL, RANDOMIZED NON-COMPARATIVE TRIAL OF NIVOLUMAB ALONE OR IN COMBINATION WITH IPILIMUMAB FOR THE TREATMENT OF PATIENTS WITH ADVANCED HYPERMUTATED SOLID TUMORS DETECTED BY A BLOOD BASED ASSAY
BCCA CODE: P1IND235

29 Jan 2019

A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers
BCCA CODE: P1TIL8
13 Dec 2018


AN OPEN-LABEL, PHASE 2 STUDY OF NERATINIB IN PATIENTS WITH SOLID TUMORS WITH SOMATIC HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR, HER2, HER3) MUTATIONS OR EGFR GENE AMPLIFICATION 

BCCA CODE: P1TPUMA201

29 Oct 2018


A Phase 1/2, Open Label, Multicenter Study of the Combination of NKTR-214, and Nivolumab, or the Combination of NKTR-214, Nivolumab and ipilimumab in Patients with Select Locally Advanced or Metastatic Solid Tumor Malignancies
BCCA CODE: P1TPIVOT02
June 2018


A Phase I Trial of MEDI-570 in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
BCCA CODE: P1PJC021
April 2018

CANADIAN PROFILING AND TARGETED AGENT UTILIZATION TRIAL (CAPTUR) A PHASE II BASKET TRIAL
BCCA CODE: P1PM1
March 2018

A phase-Ib dose-finding study of the SMAC mimetic Debio 1143 when given in combination with the anti-PD-L1 antibody avelumab to patients with advanced solid malignancies and, in an expansion cohort, to patients with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC)
BCCA CODE: P1T1143 
March 2018

A Phase I Trial of MEDI-570 in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
BCCA CODE: P1PJC021
January 2018

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors
BCCA CODE: P1TGARNET
September 2017

A phase I/II study of safety and efficacy of ribociclib (LEE011) in combination with trametinib (TMT212) in patients with metastatic or advanced solid tumors
BCCA CODE: P1TLEETMT 
September 2017

A Phase I trial of MLN0128 (Tak-228) in combination with osimertinib (AZD9291) in advanced EGFR mutation positive non-small cell lung cancer (NSCLC) after progression on a previous EGFR tyrosine kinase inhibitor.

BCCA CODE: P1PJC020

September 2017


A Phase II Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors
BCCA CODE: P1PJC022

August 2017


An open-label, dose escalation, safety, and pharmacokinetic study of CFI-402257 administered orally to patients with advanced solid tumours
BCCA CODE: P1T402257
May 2017

A phase II study of durvalumab (MEDI4736) and tremelimumab in patients with advanced rare tumours
BCCA CODE: MOIND228
April 2017

A phase I/Ib, open-label, multi-center, repeat-dose, dose-selection study of CPI-444 as single agent and in combination with atezolizumab in patients with selected incurable cancers
BCCA CODE: P1TCPI444
February 2017

A phase I/II study of CX5461
BCCA CODE: P1IND231
September 2016

A phase I/IIa study of BMS-986205 in combination with nivolumab (BMS-986558, anti PD-1 Monoclonal Antibody) in advanced malignant tumors
BCCA CODE: P1T986205
April 2016

A phase I trial of MK-3475 Plus Ziv-Aflibercept in patients with advanced solid tumours
BCCA CODE: P1PJC016
August 2015

A phase I/II study of MG1 MARABA/MAGE-A3 (MG1MA3), with and without adenovirus vaccine, with transgenic MAGE-A3 insertion (AdMA3) in patients with incurable advanced metastatic MAGE-A3 expressing solid tumours
BCCA CODE: P1IND214
July 2015
 A phase I trial of single agent trametinib (GSK1120212) in advanced cancer patients with dysfunction
BCCA CODE: P1PJC015
June 2014
SARCOMA
 
SKIN - MELANOMA
A phase III randomized, double-blind, placebo-controlled study comparing the combination of PDR001, daBRAFenib and trametinib versus placebo, daBRAFenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600 mutant melanoma
BCCA CODE: SMTCOMBII 
15 May 2018

A randomized phase III study of duration of anti-PD-1 therapy in metastatic melanoma (STOP-GAP)
BCCA CODE: SMME13
October 2016
SYMPTOM MANAGEMENT/
SUPPORTIVE CARE

A randomized, double-blind, placebo controlled crossover trial of the use of Subcutaneous Lidocaine Infusion (SCLI) for chronic cancer-related pain
BCCA CODE: LIDOCAINE
 January 2012

Sennosides PEG study
A randomized, double-blind, double-dummy, 2 treament, 2 period, cross-over comparison of Sennosides and Polyethylene Glycol for constipation in outpatients with cancer
BCCA CODE: SCTPEGSEN
April 2010
MULTIPLE
SITES

Utilization of genomic information to augment chemotherapy decision-making for people with incurable malignancies
BCCA CODE: no BCCA code available

July 2012
SOURCE: BC Cancer – Vancouver ( )
Page printed: . Unofficial document if printed. Please refer to SOURCE for latest information.

Copyright © BC Cancer. All Rights Reserved.

    Copyright © 2019 Provincial Health Services Authority